JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Perrigo Co PLC

Fermé

SecteurSoins de santé

22.02 -2.78

Résumé

Variation du prix de l'action

24h

Actuel

Min

21.76

Max

22.48

Chiffres clés

By Trading Economics

Revenu

38M

-6.4M

Ventes

-94M

1B

Rendement du dividende

4.22

Marge bénéficiaire

-0.613

Employés

8,379

EBITDA

13M

127M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+39.69% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.22%

2.54%

Date du Prochain Dividende

16 sept. 2025

Date du Prochain Détachement de Dividende

29 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

352M

3.7B

Ouverture précédente

24.8

Clôture précédente

22.02

Sentiment de l'Actualité

By Acuity

12%

88%

11 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Perrigo Co PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 juil. 2025, 13:01 UTC

Acquisitions, Fusions, Rachats

Perrigo to Sell Dermacosmetics Business to KKR With Focus on Streamlining Company

28 févr. 2025, 17:42 UTC

Principaux Mouvements du Marché

Perrigo Shares Jump on FDA's Move to Reclassify Wisconsin Infant-Formula Plant

27 févr. 2025, 23:52 UTC

Résultats

Perrigo Gets Facility Reclassification From FDA as 4Q Profit, Revenue Fall

14 juil. 2025, 12:33 UTC

Acquisitions, Fusions, Rachats

Perrigo: Business Generated About 5% of 2024 Adjusted Operating Income >PRGO

14 juil. 2025, 12:33 UTC

Acquisitions, Fusions, Rachats

Perrigo: Dermacosmetics Branded Business Generated About EUR125 Million Sales in 2024 >PRGO

14 juil. 2025, 12:32 UTC

Acquisitions, Fusions, Rachats

Perrigo: Deal Proceeds to Further Strengthen Balance Sheet >PRGO

14 juil. 2025, 12:31 UTC

Acquisitions, Fusions, Rachats

Perrigo: Deal Includes EUR300 Million Upfront Cash, Up to EUR27 Million Contingent Payments >PRGO

14 juil. 2025, 12:31 UTC

Acquisitions, Fusions, Rachats

Perrigo To Sell Dermacosmetics Branded Business to KKR Investment Vehicle >PRGO

14 juil. 2025, 12:30 UTC

Acquisitions, Fusions, Rachats

Perrigo Announces Agreement to Divest Dermacosmetics Business for Up to EUR327 Million

Comparaison

Variation de prix

Perrigo Co PLC prévision

Objectif de Prix

By TipRanks

39.69% hausse

Prévisions sur 12 Mois

Moyen 31.5 USD  39.69%

Haut 40 USD

Bas 24 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

4 ratings

2

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

25.22 / 26.85Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

11 / 374Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Perrigo Co PLC

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.